UPCC 06419: Phase 1/2 Open Label Multi-center Dose-Escalation

Build status - In Progress

Recruiting

99 years or below

All

Phase 1

1 Location

Brief description of study

This is a Phase 1/2, open-label, multicenter dose-escalation and dose-expansion trial evaluating the safety and tolerability of fimepinostat administered orally to patients with R/R lymphoma.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: lymphoma
Age: 99 years or below
Gender: All

Updated on 04 Aug 2024. Study ID: 832894

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

View email

Phone

View phone

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center

UPCC 06419: Phase 1/2 Open Label Multi-center Dose-Escalation Study to Assess the Safety Tolerability and Pharmacokinetics of Orally Administered Fimepinostat (CUDC-907) a PI3K and HDAC Inhibitor in Subjects with Relapsed and/or Refractory Lymphoma

Brief description of study

Eligibility of study

Find a site

Interested in the study